Since then, a range of ALK TKIs including ceritinib, lorlatinib, brigatinib, alectinib and repotrectinib have been explored in a preclinical NB setting as well as in several published clinical case reports (Heukamp et al, 2012; Guan et al, 2016; Infarinato et al, 2016; Iyer et al, 2016; Siaw et al, 2016; Guan et al, 2018; Alam et al, 2019; Cervantes‐Madrid et al, 2019). The gene discussed is ALK; the disease is neuroblastoma.